Vaccine News and Research

Latest Vaccine News and Research

Study detects contrasting patterns of malaria drug resistance in humans, mosquitoes

A study conducted by researchers at the Johns Hopkins Malaria Research Institute and their Zambian colleagues detected contrasting patterns of drug resistance in malaria-causing parasites taken from both humans and mosquitoes in rural Zambia.

16 Nov 2011

IAVI policy brief examines HIV vaccine funding

A new policy brief from the International AIDS Vaccine Initiative (IAVI) "summarizes data on HIV vaccine R&D funding trends originally published by the HIV Vaccines and Microbicides Resource Tracking Working Group in 2011," according to the IAVI website.

16 Nov 2011

Some public health experts raise concerns over plans to immunize Haitians against cholera, AP reports

The Associated Press/Washington Times reports on a pilot project plan by Partners In Health (PIH) and GHESKIO to vaccinate Haitians against cholera, which "has set off a debate among some public health experts who question the wisdom of the program that will inoculate only one percent of the population and could deplete the world's stock of available cholera vaccine, potentially putting people at risk in other vulnerable places."

16 Nov 2011

Pneumococcal vaccine Prevnar13 effective in seniors

Pneumococcal disease kills millions worldwide and the largest affected groups are children and the elderly. Federal health scientists now assure that the popular pneumococcal vaccine Prevnar is at least as effective as a rival vaccine at protecting adults from the sometimes-deadly infection.

15 Nov 2011

Scientists determine atomic structure of Lassa fever viral protein

Scientists at The Scripps Research Institute have determined the atomic structure of a protein that the Lassa fever virus uses to make copies of itself within infected cells.

15 Nov 2011

Midatech receives Swissmedic approval to start trial of insulin-coated gold nanoparticle

Midatech Ltd., a global leader in the design, development, synthesis and manufacture of nanomedicines, announced today it has received Swissmedic approval to start the First-in-Human clinical trial with insulin-coated gold nanoparticles, which will be coordinated through its Swiss subsidiary PharMida AG.

15 Nov 2011

Encouraging results from KAEL-GemVax GV1001 Phase II trial on NSCLC

KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that results from a Phase II trial (CTN-2006) in Stage III non-small cell lung cancer (NSCLC) patients vaccinated with the telomerase peptide GV1001 after chemoradiotherapy and an 8-year update from a phase I/II trial have been published in the November issue of Clinical Cancer, the journal of the American Association for Cancer Research.

15 Nov 2011

HIV and syphilis on the rise among MSM

Rates of HIV and syphilis are very high and rising among men who have sex with men (MSM) in New York City, reports a study in the November issue of JAIDS: Journal of Acquired Immune Deficiency Syndromes. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

15 Nov 2011

New technology speeds up 'near real-time' vaccination data collection

New technology now makes it possible to collect 'near real-time' data about whether people are having any side effects from vaccination. By studying people who received the 2009-10 swine flu vaccination in Scotland, researchers showed that this rapid reporting can add another layer of safety to future vaccination campaigns. In addition, the data collected revealed no significant safety issues in patients exposed to the vaccine.

15 Nov 2011

Lentigen, UH Case Medical Center initiate LG631 Phase I trial in glioblastoma

University Hospitals (UH) Case Medical Center, Case Western Reserve University School of Medicine and Lentigen Corporation announced today the initiation of a novel Phase I clinical trial of LG631 gene therapy for the protection of hematopoietic stem cells (HSCs) from the dose limiting toxicity of chemotherapy with Temodar.

15 Nov 2011

Sinovac third quarter sales increase 60.8% to $15.4 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter financial results for the period ended September 30, 2011.

14 Nov 2011

Soligenix third quarter revenues increase to $5,796,000

Soligenix, Inc., a development stage biopharmaceutical company, announced today its financial results for the third quarter of 2011.

14 Nov 2011

Senior UK Parliamentarians visit Bangladesh to see full impact of pneumonia on children

To mark World Pneumonia Day, a senior UK parliamentary delegation travelled to Dhaka this week to see firsthand the full impact of pneumonia on Bangladeshi children.

14 Nov 2011

IVI receives WHO prequalification for new oral cholera vaccine

Shanchol-, a new oral cholera vaccine developed through the International Vaccine Institute (IVI), an international organization established by the United Nations and based in Seoul, recently received prequalification from the World Health Organization.

13 Nov 2011

Rapid expansion of global vaccine campaign against pneumonia 'unprecedented'

"A global push to bring a vaccine against the bacterial cause of pneumonia to communities that need it most is ramping up quickly, expanding to nearly 60 countries in the next five years," PBS NewsHour's "The Rundown" reports.

11 Nov 2011

Third annual World Pneumonia Day to be observed on Saturday

The third annual World Pneumonia Day will be observed on Saturday.

11 Nov 2011

Vaccination dramatically reduces incidence of Hib disease in young children

Vaccination against Haemophilus influenzae type b, or Hib, once the most common cause of bacterial meningitis in children, has dramatically reduced the incidence of Hib disease in young children over the past 20 years, according to a study published in Clinical Infectious Diseases and available online.

11 Nov 2011

Pharmaceutical industry should invest more in NTDs

In this Forbes opinion piece, contributor Sarika Bansal examines "what needs to happen for the pharmaceutical industry, academic researchers, and other key players to begin investing more seriously in" neglected tropical diseases.

11 Nov 2011

British researchers discover receptor necessary for malaria parasite to invade red blood cells, offering new vaccine hope

Researchers from the Wellcome Trust Sanger Institute in the U.K. have "made a critical discovery about the way the most deadly species of malaria parasite invades human red blood cells," Reuters reports.

11 Nov 2011

Universally effective malaria vaccine on the horizon

Scientists are excited with a new breakthrough in development of an effective vaccine against malaria. The latest study finds how malaria acts and how the vaccine would be able to protect individuals from malaria.

10 Nov 2011